article Open AccessTop 1% cited

Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma

Annals of Surgical Oncology · 2009 · Vol. 16(4) · pp. 836–47

Matthew H. G. Katz✉(The University of Texas MD Anderson Cancer Center)Huamin Wang(The University of Texas MD Anderson Cancer Center)Jason B. Fleming(The University of Texas MD Anderson Cancer Center)Charlotte C. Sun(The University of Texas MD Anderson Cancer Center)Rosa F. Hwang(The University of Texas MD Anderson Cancer Center)Robert A. Wolff(The University of Texas MD Anderson Cancer Center)Gauri Varadhachary(The University of Texas MD Anderson Cancer Center)James L. Abbruzzese(The University of Texas MD Anderson Cancer Center)Christopher H. Crane(The University of Texas MD Anderson Cancer Center)Sunil Krishnan(The University of Texas MD Anderson Cancer Center)Jean‐Nicolas Vauthey(The University of Texas MD Anderson Cancer Center)Eddie K. Abdalla(The University of Texas MD Anderson Cancer Center)Jeffrey E. Lee(The University of Texas MD Anderson Cancer Center)Peter W. T. Pisters(The University of Texas MD Anderson Cancer Center)Douglas B. Evans(College Station Medical Center)

View via DOI Full-text PDF

Abstract

Our 27% actual 5-year survival rate for patients with resected PC is superior to that previously reported, and it is influenced by our emphasis on detailed staging and patient selection, a standardized operative approach, and routine use of multimodality therapy.

Pancreatic and Hepatic Oncology Research Neuroendocrine Tumor Research Advances Cholangiocarcinoma and Gallbladder Cancer StudiesMedicinePancreaticoduodenectomyAdenocarcinomaSurgical oncologySurgeryAdjuvant therapyMultivariate analysisSurvival rateNeoadjuvant therapyLymph node

MeSH terms

AdenocarcinomaAdultAgedAged, 80 and overAntineoplastic AgentsCombined Modality TherapyFemaleHumansMaleMiddle AgedPancreatic NeoplasmsPatient Care TeamSurvival AnalysisRadiotherapy, AdjuvantNeoadjuvant Therapy